Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SON-1010 in advanced solid tumors
NCT05352750Phase 1Active, not recruiting
- Sponsor
- Sonnet BioTherapeutics
- Start
- Apr 2022
- Primary completion
- Jun 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of SON-1010 in solid tumor (advanced stage) and soft tissue sarcoma (STS) (7 arms), sponsored by Sonnet BioTherapeutics. Primary endpoints: Safety and Tolerability of SON-1010 at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Started Apr 2022; status: active, not recruiting.
02
Drugs
SON-1010
03
Conditions
solid tumor (advanced stage)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05352750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352750.